MiNK Therapeutics closed at $10.10 on Nov 5, down 4.70%, 28.9% below its 52-week closing high. Volume of 14.8K shares was 1.24× its 20-day average (close to normal).
Split-adjusted performance: -11.5% over one month, -9.7% over six months, -21.1% over one year.
Short interest was 47.8K shares at the Oct 15 settlement, down 3.6% from the prior report (2.4% of float, 2.4 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INKTMiNK Therapeutics | $10.10 | −4.70% | −9.7% | — | — | — | $51.6M | |
| ELOXEloxx Pharmaceuticals | $12.59 | −1.18% | — | — | — | — | $50.8M | Compare |
| KLRSKalaris Therapeutics | $2.10 | +3.96% | −59.2% | — | — | — | $50.0M | Compare |
| GRMLGreenland Mines | $3.62 | −7.42% | — | — | — | — | $49.5M | Compare |
| TILInstil Bio | $6.97 | −0.29% | −13.2% | — | — | — | $47.3M | Compare |
| IMAImageneBio | $4.08 | −0.49% | −31.0% | — | — | — | $46.3M | Compare |
| CRDFCardiff Oncology | $0.7602 | −12.51% | −52.5% | −14.0% | −8882.7% | — | $59.1M | Compare |
| CGTXCognition Therapeutics | $0.6405 | −6.26% | −44.8% | — | — | — | $60.9M | Compare |
| CRBUCaribou Biosciences | $0.4069 | −8.44% | −78.4% | −43.8% | −1619.9% | — | $43.6M | Compare |
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
